Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer... ( Expects to qualify for 180 days of so...)

Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment

Date:4/14/2009

Expects to qualify for 180 days of sole marketing exclusivity

PITTSBURGH, April 14 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Hoffmann-La Roche Inc. in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Capecitabine Tablets, 150 mg and 500 mg, the generic version of Xeloda(R) Tablets, a chemotherapy treatment for breast and colorectal cancer.

Mylan believes it is the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for the product and expects to qualify for 180 days of sole marketing exclusivity once final FDA approval is obtained. Hoffmann-La Roche filed a lawsuit April 8 in the U.S. District Court for the District of New Jersey alleging infringement of U.S. Patent No. 5,472,949.

Xeloda Tablets, 150 mg and 500 mg, had approximately $447 million in sales for the 12 months ending Dec. 31, 2008, according to IMS Health. Currently, Mylan has 117 ANDAs pending FDA approval, 33 of which are potential first-to-file opportunities.

This press release includes statements that constitute "forward-looking statements," including with regard to the expected first-to-file status and pending litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward- looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the use of legal, regulatory and legislative strategies by competitors or other third parties to de
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development
2. Mylan Announces Clarinex(R) Settlement Agreement
3. Mylan Announces Intention to Purchase Remaining Interest in Matrix Laboratories and Delist Matrix from Indian Stock Exchanges
4. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
5. Mylans Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
6. Mylan Announces Transition of Chief Financial Officer
7. Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell
8. Mylan Schedules Fourth Quarter Financial Results Conference Call and Live Webcast
9. Mylan Receives FDA Approval for First-to-File Generic Depakote(R) ER
10. Mylan Declares Quarterly Preferred Stock Dividend
11. Mylan Receives Final FDA Approvals for Generic Versions of Lamictal(R) Tablets and Lamictal(R) CD

Post Your Comments:

(Date:12/16/2009)... deadly, attack is long-term goal, researchers say , , ... a tool to predict whether a patient will suffer ... stroke. , "This is an important new tool because ... stroke soon after a first stroke are more likely ... of Massachusetts General Hospital and Harvard Medical School, said ...

(Date:12/16/2009)... could help ease health and environmental concerns about the ... for changing the behavior of nanoparticles in municipal sewage ... Their study was published in ACS, journal Environmental ... UK Centre for Ecology and Hydrology and colleagues note ... nanoparticles particles less than 1/1000th the width of ...

(Date:12/16/2009)... Ensure and Encourage Access to Quality, Cost-Effective Care , ... ... of Congress have debated the best ways to rein in runaway ... reform. An important part of the ongoing discussion includes how ... care providers besides doctors of medicine (MDs) or osteopathy (DOs). ...

(Date:12/16/2009)... found very effective in the alleviation of symptoms associated with ... and a wide array of skin conditions. Currently over ... including over 50 branded BioVeda Health and Wellness Centers. ... ... 2009 -- BioVeda Health and Wellness Centers, LLC. is pleased ...

(Date:12/16/2009)... also at all-time low, government report shows, , , WEDNESDAY, ... the United States has reached almost 78 years, a ... birth in 2007, women can expect to live to ... according to the report from the U.S. Centers for ... Americans can expect to live longer than their parents, ...

Breaking Medicine News(10 mins):Health News:New Stroke Tool May Predict Early Recurrence 2 Health News:Behavior modification could ease concerns about nanoparticles 2 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5 Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 2 Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 3 Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 4 Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 5 Health News: Life Expectancy in U.S. Hits New High 2 Health News: Life Expectancy in U.S. Hits New High 3

[0] New Stroke Tool May Predict Early Recurrence [0] Behavior modification could ease concerns about nanoparticles [1] Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs [0] BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening [0] Life Expectancy in U.S. Hits New High

... - Revenue of $337 million declined 10.1 percent ... on U.S. hospital capital spending and foreign exchange- ... operations was $0.27 versus $0.26 in prior year, ... fully diluted share from continuing operations of $7.44 ...

... and Performance In-Line with GuidanceBEDFORD, Mass., May 4 Hologic, Inc. ... developer, manufacturer and supplier of premium diagnostics, medical imaging systems and ... announced its results for the quarter ended March 28, 2009. Highlights ... , Revenues of $402.0 ...

... May 4 The following is a statement by Joon ... the fear of a swine flu pandemic, a panic that ... Perhaps the original fear of swine flu was well ... a global epidemic that killed somewhere between 20 and 40 ...

... businesses shed their business attire in exchange for a fun ... of raising money for United Cerebral Palsy (UCP) of Central ... year, the theme is Camp Casual and the official Casual ... can choose to hold their event on another date if ...

... immunization gap between wealthier, poorer children is shrinking, study finds, ... from a new study is that more American children from ... , The bad news is that there,s still a wide ... protection against diphtheria, tetanus and whooping cough (pertussis), via the ...

... Project to End Prostate Cancer to Take Strides for the CauseWASHINGTON, ... and runners are hitting the pavement to ramp up their running ... End Prostate Cancer has joined forces with the ING New York ... has formed a team to run in the race on Nov. ...

Hill-Rom Reports Second Quarter Financial Results Hologic Announces Second Quarter Fiscal 2009 Operating Results The Viral Spiral - How A Meme About the Virus May Be More Contagious Than the Virus Itself Valley Businesses Shedding Their Suits to Go Casual for a Cause More Low-Income Kids Are Getting Vaccinated Team ZERO to Run to End Prostate Cancer in 2009 ING New York City Marathon

(Date:12/16/2009)... to Millennium Research Group (MRG), the global authority ... minimally invasive spinal fusion market will expand at ... through 2014, reimbursement concerns in certain segments will ... had been forecast at almost 20%. ,, MRG,s ... 2010 report finds that the ...

(Date:12/16/2009)... 16 Accuray Incorporated (Nasdaq: ARAY ), ... today that its president and chief executive officer, Euan ... 28th Annual J.P. Morgan Healthcare Conference in San Francisco ... p.m. ET. ,, A live webcast of each ... page of the Company,s Web site at http://www.accuray.com ...

(Date:12/16/2009)... HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWA) an ... $1 million in 12% per annum short term debt ... an initial drawdown of $500,000, with accrued interest and ... $500,000 with accrued interest and principal repayable in one ... becoming cashflow positive for any calendar month prior to ...

Breaking Medicine Technology:Reimbursement Difficulties With TranS1's AxiaLIF and NuVasive's XLIF Have Sceptics Talking 2 Reimbursement Difficulties With TranS1's AxiaLIF and NuVasive's XLIF Have Sceptics Talking 3 Accuray Incorporated to Present at 28th Annual J. P. Morgan Healthcare Conference 2 HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2 Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 62784 1 Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 62784 2 Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 62784 3 Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 62784 4 Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 62784 5 Prostate Hormone Therapy May Up Heart Risks 62783 1 Prostate Hormone Therapy May Up Heart Risks 62783 2 Prostate Hormone Therapy May Up Heart Risks 62783 3 Researchers demonstrate nanoscale X ray imaging of bacterial cells 11021 1 Researchers demonstrate nanoscale X ray imaging of bacterial cells 11021 2

[0] Reimbursement Difficulties With TranS1's AxiaLIF and NuVasive's XLIF Have Sceptics Talking [0] Accuray Incorporated to Present at 28th Annual J. P. Morgan Healthcare Conference [0] HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing

... Signals the Next to Start GrowingROCHESTER, N.Y., Feb. 26 ... mammals develop a single row of teeth, while sharks ... the journal Science. When completely understood, the genetic program ... re-grow missing teeth and prevent cleft palate, one of ...

... BenefitsSAN FRANCISCO, Feb. 26 The American Asthma ... to popular belief, drugs commonly used to treat ... many asthma sufferers.(Photo: http://www.newscom.com/cgi-bin/prnh/20090226/SF75648 )Dean Smith, ... said, "Drugs known as beta blockers have long ...

Other Medicine Technology:Scientists Discover Why Teeth Form in a Single Row 2 Scientists Discover Why Teeth Form in a Single Row 3 Scientists Discover Why Teeth Form in a Single Row 4 Scientists Discover Why Teeth Form in a Single Row 5 Research Finding Could Revolutionize Asthma Treatment 2 Research Finding Could Revolutionize Asthma Treatment 3 Research Finding Could Revolutionize Asthma Treatment 4

Scientists Discover Why Teeth Form in a Single Row Research Finding Could Revolutionize Asthma Treatment

... Focus Night & Day soft contact ... to protect the cornea and to relieve ... or chronic ocular pathologies such as bullous ... corneal dystrophies as well as post-surgical conditions ...

Cottle-Joseph Double Hook 12 mm wide....

Experience great vision, comfort and durability in a quarterly-replacement lens....

CV Encore Sphere are disposable soft contact lens that offers an ideal combination of convenience and performance....

Medicine Products:

Focus Night & Day Cottle-Joseph Double Hook Preference Sphere CV Encore Sphere

Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer...( Expects to qualify for 180 days of so...),Health